Published on 13 Sep 2023 on Insider Monkey via Yahoo Finance

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript September 12, 2023

Operator: Good morning, and welcome to the Altamira Therapeutics First Half 2023 Financial Results and Business Update Conference Call. On today's call are Thomas Meyer, Altamira Therapeutics' Founder, Chairman and Chief Executive Officer; and Covadonga Paneda, Chief Operating Officer. Earlier today, Altamira Therapeutics issued a news release with the first half 2023 financial results as well as a comprehensive business update. The release is available on the company's website at ir.altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or our strategies or expectations.

Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property position and our financial position as well as those described in the Risk Factors section in our annual report on Form 6-K and future filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing its views as of any subsequent date.